SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW HYBRIDS OF
PYRROLO[2,1-C][1,4]BENZODIAZEPINES AND QUINAZOLINONES AS
POTENTIAL ANTICANCER AGENTS by Earla, Vijaya Bharathi
13
The work carried in the research tenure has been compiled in the form of a thesis
entitled “Synthesis and Biological Evaluation of New Hybrids of Pyrrolo[2,1-
c][1,4]benzodiazepines and Quinazolinones as Potential Anticancer Agents”. The
main aim of this work has been to design and synthesize biologically active
quinazolinone-pyrrolobenzodiazepine conjugates and anthranilamide-
pyrrolobenzodiazepine conjugates, which exhibited DNA binding ability and
significant anticancer activity through mitochondrial mediated apoptosis.
Furthermore, the biologically active 2,3-dihydroquinazolinone-3,5-diaryl
isoxazoline/isoxazole conjugates and 2-styrylquinazolinone-3,5-diarylisoxazoline
/isoxazole conjugates have been prepared and evaluated for their anticancer activity
and cell cycle effects on MCF7 cell lines. The thesis has been divided into four
chapters.
 CHAPTER I: This chapter gives the general introduction about cancer
chemotherapy, covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c]
[1,4]benzodiazepine (PBD) antitumour antibiotics, and the objectives of the
present work.
 CHAPTER II:This chapter describes the synthesis of a series of quinazolinone-PBD
conjugates connected through simple alkane spacers and these conjugates have
been evaluated for their biological activity. This chapter is mainly focused on the
mitochondrial mediated apoptotic pathway responsible for the significant
anticancer activity.
 CHAPTER III: This chapter deals with the synthesis of new PBD hybrids by
linking anthranilamides through 4-piperazinyl alkane spacer to the C8-position
of the A ring of PBD scaffold. The present chapter is mostly focused on the DNA-
binding affinity and anticancer activity of the newly synthesized PBD hybrids.
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 CHAPTER IV: This chapter comprises of two sections; section A consists of design,
synthesis and biological evaluation of 2,3-dihydroquinazolinone-3,5-diaryl
isoxazoline/isoxazole conjugates as potent anticancer agents. Further these
conjugates areevaluated for cell cycle effects on MCF 7 cell lines.. Section B
consists of design, synthesis anticancer activity and cellcycle effects (MCF7 cell
lines) of 2-styryl quinazolinone-3,5-diarylisoxazoline/isoxazole conjugates.
 INTRODUCTION
This chapter describes the general introduction about pyrrolobenzodiazepines
and the objectives of the present work.
 PYRROLO[2,1-c][1,4]BENZODIAZEPINES
Cancer is a diseases characterized by uncontrolled growth or spread of
abnormal cells. It involves the conversion of any normal cell to a cancerous cell
showing tandem replication and cell division at much faster rate in comparison to
the normal cells and thus provides a potential target area for the development of
chemotherapeutic agents. It is now clear that chemotherapy’s most effective role in
solid tumours is as an adjuvant to initial therapy by surgical or radiotherapeutic
procedures. Chemotherapy becomes critical to effective treatment because only
systemic therapy can attack micrometastases. These agents can be categorized into
functional subgroups like alkylating agents, antimetabolites, antibiotics, and
antimitotics. The pyrrolo[2,1-c][1,4]benzodiazepines belonging to the class of DNA-
interactive antitumour antibiotics have the potential as regulators of gene expression
with possible therapeutic application in the treatment of genetic disorders including
cancer. The first PBD antitumour antibiotic anthramycin has been described by
CHAPTER-I
15
Leimgruber et. al., in 1963, and since then a number of compounds have been
developed on the PBD ring system leading to some efficient DNA binding ligands.
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PBD’s are a family of potent naturally occurring low molecular weight
antitumour antibiotics originally isolated from various Streptomyces species. Their
common interaction with DNA has been extensively investigated and it is
considered unique since they bind within the minor groove of DNA forming a
covalent aminal bond between the C11-position of the central B-ring and the N2
amino group of guanine base. A number of naturally occurring and synthetic
compounds based on PBD ring system, such as anthramycin, tomaymycin, DC-81
and its dimers (presently, one of the dimer SJG-136 is under clinical evaluation),
have shown varying degrees of DNA binding affinity and anticancer activity.
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In search for new potential anticancer drugs, we designed and synthesized
combilexins, in which DNA intercalator is linked to a minor groove binding
component. A new type of DNA intercalator comprising of quinazolinone moiety
has been tethered by ether linkage to the PBD ring system and these have been
evaluated for their biological activity. An attempt, based on the in vitro cytotoxic
activity exhibited in these compounds made to rationalize their mechanism of action
through cell cycle analysis and DNA interaction studies. Cell cycle phase
distribution and apoptosis is measured using flow cytometry. The DNA binding
characteristics of these conjugates have been evaluated by thermal denaturation
studies. A molecular modeling study has been carried out for a set of compounds
22a-f and 25a-f and calculated their binding score. Further MD simulations have also
been carried out for the compounds 22b, 25b and 25c. One of the representative
compounds 25c of this series has been tested against a panel of 57 human cancer cell
lines. Further, compounds 22b and 25c induce marked influence on the cell cycle
phase distributions with significant G1 arrest in A-375 cells, followed by the
induction of apoptosis through mitochondrial mediated pathway along with
suppression of NF-B.
 SYNTHESIS OF QUINAZOLINONE LINKED PYRROLOBENZODIAZEPINE (PBD)
CONJUGATES
Synthesis of quinazolinone -pyrrolobenzodiazepine conjugates (22a-f and 25a-
f) has been carried out by employing the commercially available vanillin (1) as the
starting material. Oxidation of vanillin to form the corresponding carboxylic acid
followed by acid-catalyzed esterification with methanol provided methyl benzoate
in quantitative yield. This is followed by benzylation and nitration by employing the
literature method provides 4-benzyloxy-5-methoxy-2-nitrobenzoic acid (6). This has
been further coupled to L-proline methyl ester to afford the intermediate 7, which
upon reduction with DIBAL-H produces the corresponding aldehyde 8. The
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aldehyde group of this compound has been protected with EtSH/TMSCl to give 9,
which upon debenzylation provides the key intermediate 10 (Scheme 1).
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Scheme 1. Reagents and conditions: (i) NH2SO3H, NaClO2, H2O, rt, 2 h, 90%; (ii) H2SO4, MeOH,reflux, 4 h, 85%; (iii) benzylbromide, K2CO3, acetone, reflux, 24 h, 92%; (iv) SnCl4, fumingHNO3, CH2Cl2, 5 min, -25 oc, 78%; (v) 2N LiOH, MeOH, H2O, THF (1:1:3), rt, 12 h, 83%; (vi)SOCl2, C6H6, L-proline methylester hydrochloride, THF- H2O, 1-2 h, rt, 85%; (vii) DIBAL-H,CH2Cl2, 1-1.30 h, -78 oC, 65%; (viii) EtSH, TMSCl, CH2Cl2, 8-12 h, rt, 72%; (ix) BF3.OEt2, EtSH,CHCl3, rt, 8 h, 75%.
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The quinazolinone precursors required for the preparation of the desired PBD-
conjugates have been prepared as shown in Scheme 2. This synthetic strategy is
involves to the cyclization of anthranilic acid to benzoxazinone followed by
coupling with aromatic amines.  Starting materials 12 and 16 has been obtained by
condensation of commercially available 5-hydroxy anthranilic acid (11) and
anthranilic acid (15) with acetic anhydride respectively. The compound 12 on
coupling with substituted anilines in glacial acetic acid gives the compounds 13ae.
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These compounds on subsequent etherification with dibromo alkanes afford
quinazolinone precursors (14af). The other types of quinazolinones have been
obtained by reaction of compound 16 with 4-aminophenol to give compound 17,
which upon etherification by employing dibromo alkanes give compounds 18a–c.
Compounds 19a–c have been prepared by employing benzaldehyde and 18a–c
(Scheme 3).
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Scheme 2. Reagents and conditions: (i) (CH3CO)2O, 160-180 oC, 1 h; (ii) R-NH2, 180 oC, 2 h;(iii) dibromoalkanes, K2CO3, acetone, reflux, 24 h.
Scheme 3. Reagents and conditions: (i) (CH3CO)2O, 160-180 oC, 1 h; (ii) 4-amino phenol, 180 oC,2 h; (iii) dibromoalkanes, K2CO3, acetone, reflux, 24 h; (iv) benzaldehyde, glacial acetic acid,120 oC, 12 h.
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PBD subunit precursors required for the preparation of these conjugates have
been synthesized by employing the procedure reported in the literature. PBD
subunit precursors required for the preparation of these conjugates have been
synthesized by employing the procedure reported in the literature. Accordingly
(2S)-N-[4-(hydroxy)-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carb-oxaldehyde
diethyl thioacetal (10) has been prepared and linked to quinazolinone precursors
14af, 18ac and 19ac by etherification in the presence of K2CO3 and acetone to
provide intermediates 20af and 23af. To produce 22af and 25af the nitro
thioacetals 20af and 23af have been reduced to the amino thioacetals 21af and
24af with SnCl2.2H2O in refluxing MeOH and then cyclized by treatment with
HgCl2 and CaCO3 in MeCN-H2O (Schemes 4 and 5).
22a: X = H, Y = H, Z = F, n = 3
22b: X = H, Y = Cl, Z = F, n = 3
22c: X = Cl, Y = H, Z = Cl, n = 2
22d: X = CH3, Y = H, Z = iodo, n = 222e: X = CH3, Y = H, Z = iodo, n = 322f: X = H, Y = H, Z = OCH3, n = 3
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Scheme 4. Reagents and conditions: (i) 14a-f, K2CO3, dry acetone, reflux, 24 h, 80-85%; (ii) SnCl2.2H2O,CH3OH, reflux, 6 h; (iii) HgCl2, CaCO3, CH3CN-H2O, (4:1), 12 h, 55-58%.
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Scheme 5. Reagents and conditions: (i) 18ac and 19ac, K2CO3, dry acetone, reflux, 24 h, 8088%; (ii)SnCl2.2H2O, CH3OH, reflux, 6 h; (iii) HgCl2, CaCO3, CH3CN-H2O, (4:1), 12 h, 5558%.
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The thermal denaturation studies show that hybrid agents (22a-f and 25a-f)
possess good DNA binding ability compared to DC-81. Our finding suggested that
these hybrid agents bind to DNA more efficiently than DC-81. In addition,
molecular modeling study has been carried out for a set of quinazolinone-PBDs
(22a-f and 25a-f) in order to rank them through their complementarity to the
CGCGATCGCG, according to their interaction energies with B-DNA. The optimal
number of methylene linkers calculated from the GOLD docking and the
experimental numbers are in reasonably good agreement.
Compounds 22a–f, 25a, 25b, and 25d–f have exhibited significant anticancer
activity against eleven cell lines with GI50 values ranging from <0.1 to 26.2 M in
comparison to adriamycin (GI50 from 0.1–7.25 M). According to the in vitro
screening data, compound 25c has significant cytotoxicity against all the cancer cell
lines with GI50 values ranging from 0.06 to 0.43 M and the mean GI50 value for the
compound 25c is 0.27 M, which exhibits an interesting profile of activity for various
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cell lines, indicating that this compound 25c has the potent broad-spectrum
anticancer activity. Further compounds 22b and 25c induced strong sub G1/G0
arrest of the cell cycle followed by apoptosis, in A-375 cells. Two promising
compounds 22b and 25c induced the release of cytochrome c, activation of caspase-3,
cleavage of PARP and subsequent cell death. Further, these compounds when
treated with A375 cells show the characteristic features of apoptosis like
enhancement in the levels of p53, p21 and p27 inhibition of CDK2 and suppression
of NF-B. Also these compounds 22b and 25c control cell proliferation by regulating
anti apoptotic genes like Bcl-2. Hence the data obtained suggests that the ability of
these PBD conjugates to activate p53 and inhibit NF-B could be useful for the
development of anticancer agents with a greater therapeutic potential for tumour
suppression (Bioorg. Med. Chem. 2010, 18, 526-542, Patent filed 2598/DEL/08 (India),
PCT/IN2009/000400).
In an effort to establish new candidates with improved anticancer activity,
pyrrolobenzodiazepine derivatives bearing anthranilamide moiety synthesized and
their DNA interaction has been evaluated by thermal denaturation studies. The
cytotoxic studies of the hybrid agents on human cancer cell lines indicate most of the
hybrids induced higher cytotoxicity.
 SYNTHESIS OF C8-LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS WITH
ANTHRANILAMIDE
The synthetic strategies adopted to obtain the target compounds are depicted
in Schemes 12. The precursors in the present study is the 28 anthranilamides of
formula 4 and (2S)-N-[4-(n-bromoalkyl)oxy-5-methoxy-2-nitro-benzoyl]pyrrolidine-
2-carboxaldehyde dieth-ylthioacetal51 of formula 5 have been prepared by literature
methods.
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Scheme 1. Reagents and conditions: (i) N-boc piperazine, 1,4-dioxane, reflux, 4 h; (ii) R-CHO,
NaCNBH3, MeOH, CH3COOH, rt, 22 h; (iii) TFA, CH2Cl2, rt, 5 h
The precursors 4af have been prepared as shown in Scheme 1.
Isatoicanhydride 1a or 6-chloroisatoicanhydride 1b has been treated with N-boc
piperazine in 1:1.2 M ratio, and refluxed in 1,4-dioxane to give the 4-(2-
aminobenzoyl)N-boc piperazine 2a and 4-(2-amino-5-chlorobenzoyl) N-boc
piperazine 2b respectively in almost quantitative yield. These compounds 2a and 2b
upon reductive amination with different aromatic aldehydes by using
sodiumcyanoborohydride (NaCNBH3) in methanol with catalytic amount of acetic
acid afford compounds 3af, which on further deprotection with triflouroaceticacid
give precursors 4af (Scheme 1). Synthesis of anthranilamide-PBD conjugates (8a-l)
has been carried out by employing (2S)-N-[4-(bromoalkoxy)-5-methoxy-2-
nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal (5a-c) as the starting
material. The nitro thioacetal intermediate (5a-c) was coupled with anthranilamide
precursors of formulae 4af to give nitrothioacetal intermediates 6al. The nitro
group of this compound has been efficiently reduced employing SnCl2.2H2O to
afford the corresponding aminothioacetal 7a-l. Deprotection of the thioacetal group
with HgCl2 and CaCO3 afford the desired PBD hybrids 8a-l (Scheme 2).
23
(i)N
NO2O
H3CO
O
CH(SEt)2
5ac
Br ( )n
N
NO2O
H3CO
CH(SEt)2( )nNH
N
R
O
N
X
(iii)
n = 1, 3, 4
N
O
H3CO
( )nNH
N
R
O
N
X
N
O
H
4af
a: R = 3,4,5-trimethoxy phenyl, X = H, n = 1
b: R = 3,4,5-trimethoxy phenyl, X = H, n = 3
c: R = 3,4,5-trimethoxy phenyl, X = H, n = 4
d: R = 4-pyridinyl, X = H, n = 1
e: R = 4-pyridinyl, X = H, n = 3
f: R = 4-pyridinyl, X = H, n = 4
g: R = 2-napthyl, X = H; n = 1
h: R = 2-napthyl, X = H, n = 3
i: R = 2-napthyl, X = H, n = 4
j: R = 3-chromenyl, X = H, n = 3
k: R = 2-napthyl, X = Cl, n = 3
l: R = 3-chromenyl, X = Cl, n = 3
6al
8al
(ii)
N
NH2O
H3CO
CH(SEt)2( )nNH
N
R
O
N
X
7al
Scheme 2. Reagents and conditions: (i) dibromoalkane, K2CO3, acetone, reflux, 24 h; (ii) SnCl2.2H2O,
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BIOLOGICAL ACTIVITY OF C8-LINKED PYRROLO[2,1-C][1,4]BENZODIAZEPINE
HYBRIDS
Compounds 8a–l have been evaluated for their in vitro anticancer activity in
selected human cancer cell lines of MCF7 (breast), A2780 (ovarian), Colo205 (colon),
PC3 (prostate), SiHa (cervix), A-549 and Hop62 (lung) and KB (Leukemia) by
sulforhodamine B (SRB) assay. The compounds exhibiting GI50 ≤ 10-5M (10 M) are
considered to be active on the respective cell lines. A protocol of 48 h continuous
drug exposure was used and a sulforhodamine B (SRB) protein assay was used to
estimate cell viability or growth. The concentration causing 50% cell growth
inhibition (GI50) compared with the control was calculated. The results show that all
the new compounds are significantly cytotoxic, with the molar concentration of the
drug that inhibits 50% net cell growth inhibition (GI50) ranging from 0.13 to 29 M.
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Thermal denaturation studies showed that these compounds stabilized the
thermal helix coil or melting stabilization (ΔTm) for the CT-DNA duplex at pH 7.0,
where PBD/DNA molar ratio is 1:5. Interestingly, all the anthranilamide–PBD
conjugates (8a–l) elevate the helix melting temperature of CT-DNA in the range of
4.1–8.6 oC at 0 h and also examined after 18 h incubation at 37 o C. Compound 8f
showed the highest ΔTm of 8.6 oC at 0 h which increased up to 9.2 oC after 18 h
incubation. All the compounds 8a–l have shown better fit in the minor groove of
DNA, leading to enhanced binding affinity compared to DC-81. Moreover it is
interesting to note that the incorporation of a piperazine moiety in the linker spacer
in all the anthranilamide-PBD conjugates have exhibited potent DNA-binding
affinity with  ΔTm values ranging from  4.1–8.6 oC.
Among all the PBD conjugates, three potent compounds 8g, 8h and 8j have
been tested for cell viability of A375 cell lines by MTT assay. The significant
inhibition of cell proliferation of A375 cell line showed by these PBD conjugates
prompted us to further study the effect of them on cell cycle distribution as well as
caspase-3 analysis (Bioorg. Med. Chem. Lett. 2010, in press).
In continuation to our efforts on the design of new anticancer agents, we became
interested in the development of new hybrid molecules that consists of two
phamacophores in a single molecule with an intention to enhance the efficacy of
such compounds.31 In this context, 3,5-diaryl isoxazoline/isoxazoles have been
linked to quinazolinones through different alkane spacers and as well as through a
piperazine side armed alkane spacer. These new hybrids have been evaluated for
their anticancer activity. In view of this promising activity, it has been considered of
interest to investigate their role in cell cycle effects of MCF7 cell lines. Further, some
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detailed biological studies related to the mechanism aspects have been carried out
for some representative compounds. This chapter is divided into two sections.
 SECTIONA
 SYNTHESIS OF 3,5-DIARYL ISOXAZOLINE/ISOXAZOLE LINKED 2,3-
DIHYDROQUINAZOLINONE HYBRIDS
The synthesis of 3,5-diaryl isoxazoline and isoxazole derivatives (5a,b and 10a,b)
24,25 has been carried out from aldehydes 1a,b and 6 as the starting materials.
Reaction of these aldehydes with hydroxylamine in a MeOH/H2O (3:1) solution
produces the corresponding oximes 2a,b and 7 in high yields. Olefins 3a and 8a
have been obtained by the reaction of aldehydes 6 and 1b respectively with
methyltriphenyl phosphonium bromide, in the presence of sodium hydride. Then
these olefins 3a and 8a have been coupled to oximes 2a and 7 to provide the
corresponding tertiary butyl dimethyl silyl (TBDMS) protected isoxazolines 4a and
9a. Similarly, TBDMS protected isoxazoles 4b and 9b have been prepared by
employing alkynes 3b and 8b and oximes 2b and 7. Further, these compounds 4a,b
and 9a,b upon deprotection with tetrabutylammonium fluoride give the desired
precursors (5a,b and 10a,b). The compound 11 has been obtained by etherification of
compound 5a as shown in Scheme 1.
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Scheme 1. Reagents and conditions: (i) NH2OH.HCl, NaHCO3, CH3OH:H2O (3:1), 0 oC, then rt, 6 h;
(ii) 13% aq NaOCl, Et3N, CH2Cl2, 0 oC, then rt, 24 h; (iii) TBAF, THF, rt, 2 h; (iv) 1,5-dibromo pentane,
K2CO3, DMF, rt, 24 h.
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The synthesis of dihydroquinazolinones is outlined in Scheme 2. Compounds
12a,b have been treated with benzamide in presence of N,N-dimethylacetamide
(DMAC) to give compounds 13a,b respectively.14 These upon etherification with
dibromoalkanes using K2CO3 in DMF provide the 2,3-dihydroquinazolinone
precursors (14a–d). Compound 14d has been coupled with N-boc piperazine to
obtain compound 15, which upon deprotection gives compound 16.
The synthesis of hybrid compounds 17a–d and 18a–d has been carried out from
the compounds 14a–d and 3,5-diaryl isoxazoline/isoxazole precursors (5a,b and
10a,b) using K2CO3 in DMF. The other hybrid (19) has been prepared from
compounds 11 and 16 as shown in Scheme 3.
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Scheme 2. Reagents and conditions: (i) Benzamide, p-toulene sulfonicacid monohydrate,
N, N-dimethylacetamide, rt, 2 h; (ii) Br(CH2)nBr, K2CO3, DMF, rt, 24 h; (iii) N-boc piperazine,
K2CO3, DMF, rt, 24 h; (iv) TFA, CH2Cl2, rt, 12 h.
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Scheme 3. Reagents and conditions: (i) K2CO3, DMF, rt, 24 h.
All the new 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone
hybrids (17a–d, 18a–d and 19) through different alkane spacers as well as through
piperazine side-armed alkane spacers. Among the hybrid compounds prepared,
compound 17c has exhibited significant anticancer activity against nineteen cancer
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cell lines with GI50 values less than 1 M. The other compounds have also exhibited
potent anticancer activity against MCF7 and PC3 cancer cell lines. The most
promising compound among this series has been evaluated for cell cycle effects on
MCF7 cell lines. (Patent filed 2602/DEL/08 (India), PCT/IN2009/000490, Manuscript
under preparation)
 SECTION B
 SYNTHESIS OF 3,5-DIARYL ISOXAZOLINE/ISOXAZOLE LINKED STYRYLQUINAZOLINONE
HYBRIDS
The synthesis of styrylquinazolinones is outlined in Scheme 1. The first synthetic
step involved the condensation of anthranilic acid (1) with acetic anhydride to afford
the desired benzoxazinone (2) in quantitative yield. After evaporation of the excess
of anhydride under reduced pressure, the crude product was used without any
further purification. The compound 2 on heating with 4-aminophenol  at 160–180 °C
for 2 h in oil bath gives 3, which upon etherification by employing dibromoalkanes
yields compounds 4ac. These analogues on reflux with benzaldehyde in acetic acid
provide the compounds 5ac.
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Scheme 1. Reagents and conditions: (i) (CH3CO)2O, reflux, 1 h; (ii) p-aminophenol, 180 oC, 2 h;
(iii) dibromo alkanes, K2CO3, acetone, reflux, 12 h; (iv) benzaldehyde, CH3COOH, reflux, 12 h.
The synthesis of precursors 3,5-diaryl-isoxazoline and isoxazole precursors 6a,b
and 7ac has been carried out as described in the chapter IV section A. The synthesis
of styrylquinazolinone linked 3,5-diaryl-isoxazoline/isoxazole hybrids (8ad, and
9ad) has been carried out from compounds 5ac and isoxazoles/ isoxazolines (6ab
and 7ac) using K2CO3 in acetone as shown in Scheme 2. The other hybrids (13a and
13b) have been prepared from the reaction between 10b,c which has been prepared
by etherification of hydroxyl isoxazoles (7a,c) with 1,5 dibromo pentane and
compound 12, which in turn has been obtained by deprotection of compound 11,
prepared from 5c by reaction with N-boc piperazine in DMF and K2CO3 at room
temperature as shown in Scheme 3 .
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Scheme 2. Reagents and conditions: (i) K2CO3, DMF, rt, 24 h.
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The compounds prepared have exhibited significant anticancer activity against
MCF7 and PC3 cancer cell lines with GI50 values ranging from <0.1 to >100 M
concentration. Amongst all the hybrids, the two promising compounds 8a and 9a
have been evaluated for cell cycle effects on MCF7 cell lines. The compounds 8a and
9a have shown more cells in sub G1 phase indicating cell death. Further biological
studies related to mechanism aspects are in progress (Manuscript under
preparation)
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Scheme 3. Reagents and conditions: (i) 1,5-dibromo pentane, K2CO3, DMF, rt, 24 h; (ii) N-boc piperazine
K2CO3, DMF, rt, 24 h; (iii) TFA, CH2Cl2, rt, 12 h; (iv) 10b,c, K2CO3, DMF, rt, 24 h.
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In this study, by employing hybridization concept, we have identified potent
anticancer compounds that are more efficient than their individual parent moieties.
Hence, this concept might through more promising for the development of lead
molecules.
